Physician profile
Emilie A Breeding
NPI 1174077333
$39,775.84
in general payments reported to CMS, 2019-2025
27 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $1,219 · 2023: $13K · 2024: $8,624 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $9,333 · Travel and Lodging: $1,596 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,125.00 |
| Food and Beverage | $9,332.87 |
| Travel and Lodging | $1,596.28 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,044.10 | 2021-2025 | |
| Neos Therapeutics, Lp | $3,303.23 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Aytu Biopharma, INC. | $1,650.00 | 2025 | |
| Axsome Therapeutics, INC. | $1,470.48 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $1,202.21 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $601.02 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $580.52 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $564.32 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $510.48 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $440.52 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $438.10 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $370.97 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $333.29 | 2021-2023 | Jornay Pm |
| Almatica Pharma LLC | $249.94 | 2023-2025 | Loreev Xr, Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.85 | 2022-2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $182.88 | 2022-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $151.35 | 2023-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $123.97 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $87.76 | 2023-2025 | Trintellix |
| Noven Therapeutics, LLC | $68.20 | 2022-2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $48.78 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $44.87 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $18.33 | 2022 | |
| Indivior INC. | $14.62 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.49 | 2025 | |
| Tempus Ai, INC | $13.81 | 2024 | |
| Biogen, INC. | $13.75 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilie Breeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.